MCID: VSC003
MIFTS: 58

Visceral Leishmaniasis

Categories: Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 15
Leishmaniasis, Visceral 44 73
Kala-Azar 12 3
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 55

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD10 33 B55.0 B55.9
ICD9CM 35 085.0
MeSH 44 D007898
NCIt 50 C34771
SNOMED-CT 68 186803007 48115004
UMLS 73 C0023290

Summaries for Visceral Leishmaniasis

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to leishmaniasis and hemophagocytic lymphohistiocytosis. An important gene associated with Visceral Leishmaniasis is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Amphotericin B and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related phenotypes are digestive/alimentary and cellular

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

Wikipedia : 76 Visceral leishmaniasis (VL), also known as kala-azar (UK: /ˌkɑːlə əˈzɑːr/), black fever, and Dumdum... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 32.9 IFNG IL10 IL4 LMLN NOS2 SLC11A1
2 hemophagocytic lymphohistiocytosis 31.7 CXCL8 IFNG IL10 TNF
3 fascioliasis 31.2 ALB IFNG IL10
4 arthritis 31.2 CXCL8 IFNG IL10 TNF
5 mixed connective tissue disease 31.1 IFNG IL10 TNF
6 sleeping sickness 31.1 IL10 NOS2 PGD
7 acquired immunodeficiency syndrome 31.1 ALB IFNG IL10 IL2 TNF
8 connective tissue disease 31.0 IFNG IL10 TLR9 TNF
9 hematopoietic stem cell transplantation 31.0 IFNG IL10 IL2 TNF
10 hemorrhagic fever 31.0 ALB IFNG IL10 TNF
11 tuberculous meningitis 31.0 CXCL8 TLR2 TNF
12 hepatopulmonary syndrome 30.9 ALB NOS2 TNF
13 lymphopenia 30.8 FOXP3 IFNG IL2
14 myeloma, multiple 30.4 ALB CXCL8 IL2 TLR9 TNF
15 chagas disease 30.2 CXCL8 IFNG IL10 IL2 NOS2 TLR2
16 chronic granulomatous disease 30.2 IFNG TLR9 TNF
17 psoriasis 30.0 CXCL8 IFNG IL10 IL2 IL4 TLR9
18 systemic lupus erythematosus 30.0 ALB IFNG IL10 IL2 IL4 TLR9
19 common variable immunodeficiency 30.0 FOXP3 IFNG IL10 IL2 IL4 TLR9
20 meningitis 30.0 ALB CXCL8 IFNG IL10 TLR2 TLR9
21 rheumatoid arthritis 29.7 CXCL8 FOXP3 IFNG IL10 IL2 IL4
22 cutaneous leishmaniasis 29.7 FOXP3 IFNG IL10 IL4 LMLN PGD
23 trypanosomiasis 29.4 ALB CXCL8 IFNG IL10 IL2 IL4
24 malaria 28.4 ALB CXCL8 FOXP3 IFNG IL10 IL2
25 mycoplasmal pneumonia 11.2 IFNG IL4
26 punctate inner choroidopathy 11.2 IL10 TNF
27 hyperlucent lung 11.1 IFNG IL10 IL4
28 baylisascariasis 11.1 IFNG IL10 IL4
29 oral tuberculosis 11.1 IL2 TNF
30 tropical endomyocardial fibrosis 11.1 IL10 IL4 TNF
31 endomyocardial fibrosis 11.1 IL10 IL4 TNF
32 campylobacteriosis 11.1 IFNG SLC11A1 TLR4
33 atopic keratoconjunctivitis 11.1 IFNG IL2 IL4
34 chronic graft versus host disease 11.1 ALB IFNG IL10
35 paranasal sinus disease 11.1 IFNG IL10 IL4
36 variola major 11.1 IFNG IL2 TLR4
37 chronic active epstein-barr virus infection 11.1 IFNG IL10 IL2
38 autoimmune myocarditis 11.1 IFNG IL2 TNF
39 spotted fever 11.0 IFNG IL10 TNF
40 vulvovaginal candidiasis 11.0 IFNG IL2 IL4
41 plasmodium vivax malaria 11.0 IFNG IL10 TNF
42 multidrug-resistant tuberculosis 11.0 IL10 SLC11A1 TNF
43 post-transplant lymphoproliferative disease 11.0 IL10 SLC11A1 TNF
44 hyper ige syndrome 11.0 IFNG IL4 TLR2
45 aphthous stomatitis 11.0 IL10 IL4 TNF
46 pouchitis 11.0 CXCL8 IL10 TLR4
47 rasmussen encephalitis 11.0 IFNG IL4 TNF
48 polyradiculoneuropathy 11.0 ALB IFNG IL10
49 posterior uveitis 11.0 IFNG IL2 TNF
50 mycobacterium chelonae 11.0 CXCL8 TLR2

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.29 IL2 IFNG ALB IL10 FOXP3 NOS2
2 cellular MP:0005384 10.26 IL10 FOXP3 IL2 IFNG ALB TLR2
3 hematopoietic system MP:0005397 10.26 FOXP3 IL2 IFNG IL10 NOS2 TLR4
4 homeostasis/metabolism MP:0005376 10.23 IL10 FOXP3 IL2 IFNG ALB IL4
5 immune system MP:0005387 10.21 IL10 FOXP3 IL2 IFNG NOS2 TLR4
6 endocrine/exocrine gland MP:0005379 10.15 IL10 FOXP3 IL2 IFNG ALB TLR2
7 mortality/aging MP:0010768 10.13 IL10 FOXP3 IL2 IFNG ALB NOS2
8 liver/biliary system MP:0005370 10.07 IL2 IFNG ALB IL10 FOXP3 NOS2
9 integument MP:0010771 10.01 IL10 FOXP3 IFNG IL4 TLR2 NOS2
10 neoplasm MP:0002006 9.91 IL2 IFNG ALB IL10 NOS2 TLR4
11 renal/urinary system MP:0005367 9.76 FOXP3 IFNG ALB NOS2 TLR4 IL4
12 respiratory system MP:0005388 9.61 FOXP3 IL2 IFNG IL10 NOS2 TLR4
13 vision/eye MP:0005391 9.23 IL10 FOXP3 IL2 IFNG NOS2 TLR4

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 14956 5280965
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
6
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1263-89-4, 7542-37-2 165580
7
Meglumine antimoniate Experimental, Investigational Phase 4,Early Phase 1 133-51-7
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Cholagogues and Choleretics Phase 4,Phase 3,Not Applicable
15 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
16 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Not Applicable
17 Anesthetics Phase 4
18 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
20
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
21
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
22
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
23
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3 10043-01-3
24 tannic acid Approved, Nutraceutical Phase 3
25
Tocopherol Approved, Investigational, Nutraceutical Phase 3 1406-66-2 14986
26
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
27 Antiviral Agents Phase 3,Not Applicable
28 Interleukin-2 Phase 3
29 Analgesics Phase 3
30 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3
31 Analgesics, Non-Narcotic Phase 3
32 Vaccines Phase 2, Phase 3,Phase 3,Phase 1
33 Peripheral Nervous System Agents Phase 3
34 Vitamins Phase 3,Not Applicable
35 Anti-HIV Agents Phase 3
36 Anti-Retroviral Agents Phase 3
37 Tocopherols Phase 3
38 Tocotrienols Phase 3
39 Tocotrienol Investigational, Nutraceutical Phase 3 6829-55-6
40 Soybean oil, phospholipid emulsion Phase 2
41 Parenteral Nutrition Solutions Phase 2
42 Pharmaceutical Solutions Phase 2
43 Antibodies Phase 1, Phase 2,Not Applicable
44 Immunoglobulins Phase 1, Phase 2,Not Applicable
45 Fat Emulsions, Intravenous Phase 2
46 Soy Bean Nutraceutical Phase 2
47 Thromboplastin Phase 1
48
Acetylcysteine Approved, Investigational Not Applicable 616-91-1 12035
49
Zinc Approved, Investigational Not Applicable 7440-66-6 23994
50
Erythromycin Approved, Investigational, Vet_approved Not Applicable 114-07-8 12560

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
3 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
4 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
5 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
6 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
7 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
8 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Unknown status NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
9 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
10 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
11 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
12 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
13 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
14 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
15 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
16 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
17 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
18 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
19 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
20 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
21 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
22 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
23 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
24 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
25 A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
26 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
27 Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
28 Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
29 Combination Chemotherapy for the Treatment of Indian Kala-Azar Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
30 A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis. Completed NCT00381394 Phase 2 sitamaquine
31 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
32 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
33 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
34 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Recruiting NCT02687971 Phase 2 Miltefosine
35 A Study of a New Leishmania Vaccine Candidate ChAd63-KH Recruiting NCT02894008 Phase 2 ChAd63-KH
36 Short Course Regimens for Treatment of PKDL (Sudan) Not yet recruiting NCT03399955 Phase 2 Paromomycin;Ambisome;Miltefosine
37 Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
38 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
39 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
40 SCH708980 With and Without AmBisome for Visceral Leishmaniasis Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
41 Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India Completed NCT00486382 Phase 1
42 Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers Completed NCT02071758 Phase 1
43 Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL Completed NCT00982774 Phase 1
44 Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Completed NCT01484548 Phase 1
45 Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine Unknown status NCT01138956 Not Applicable N-acetylcysteine;Pentavalent antimonial
46 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia Completed NCT02148822
47 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Completed NCT01240473 Not Applicable Randomized trial for treatment of kala azar in Bangladesh
48 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01328457 Not Applicable Paromomycin sulfate
49 Immunogenetics of Visceral Leishmaniasis Completed NCT00342823
50 Amphotericin B Treatment in Visceral Leishmaniasis Completed NCT00310505 Not Applicable Amphotericin B deoxycholate given as daily administration

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

41
Bone, Bone Marrow, Liver, Spleen, Testes, T Cells, Skin

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 863)
# Title Authors Year
1
Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis. ( 29421940 )
2018
2
Exploring sand fly salivary proteins to design multi-epitope subunit vaccine to fight against visceral leishmaniasis. ( 29377223 )
2018
3
Visceral leishmaniasis presenting with pancytopenia and circulating blastlike lymphocytes. ( 29930152 )
2018
4
Brain Parenchyma (pons) Involvement by Visceral Leishmaniasis: A Case Report. ( 29963097 )
2018
5
NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis. ( 29867949 )
2018
6
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. ( 29448040 )
2018
7
Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. ( 29953494 )
2018
8
Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia. ( 29375842 )
2018
9
Potential application of rLc36 protein for diagnosis of canine visceral leishmaniasis. ( 29412359 )
2018
10
Environmental factors associated with canine visceral leishmaniasis in an area with recent introduction of the disease in the State of Rio de Janeiro, Brazil. ( 29412315 )
2018
11
Canine Visceral Leishmaniasis; A Seroepidemiological Survey in Jiroft District, Southern Kerman Province, Southeastern Iran in 2015. ( 29963087 )
2018
12
Diagnostic lipid changes in patients with visceral leishmaniasis. ( 29848097 )
2018
13
Positive Influence of Behavior Change Communication on Knowledge, Attitudes, and Practices for Visceral Leishmaniasis/Kala-azar in India. ( 29386327 )
2018
14
High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran. ( 29860572 )
2018
15
Epidemiological aspects of human and canine visceral leishmaniasis in State of Alagoas, Northeast, Brazil. ( 29412243 )
2018
16
Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). ( 29444079 )
2018
17
Correction: B Cell: T Cell Interactions Occur within Hepatic Granulomas during Experimental Visceral Leishmaniasis. ( 29894507 )
2018
18
Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B. ( 29956831 )
2018
19
Molecular detection of Leishmania (Leishmania) infantum in phlebotomine sandflies from a visceral leishmaniasis endemic area in northwestern of SALo Paulo State, Brazil. ( 29373820 )
2018
20
The genetically determined production of the alarmin eosinophil-derived neurotoxin is reduced in visceral leishmaniasis. ( 29193305 )
2018
21
Liposomal Elongation Factor-1I+ Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. ( 29441060 )
2018
22
Eosinophilic inflammation in lymph nodes of dogs with visceral leishmaniasis. ( 29920692 )
2018
23
Some aspects of entomological determinants of Phlebotomus orientalis in highland and lowland visceral leishmaniasis foci in northwestern Ethiopia. ( 29438419 )
2018
24
Immunohaematological and rheological parameters in canine visceral leishmaniasis. ( 29846458 )
2018
25
Description of Leishmania species among dogs and humans in Colombian Visceral Leishmaniasis outbreaks. ( 29936036 )
2018
26
Mediastinal cystic mass as atypical location of visceral leishmaniasis. ( 29398008 )
2018
27
Immunoprophylactic Potential of a Cocktail of Three Low Molecular Weight Antigens of <i>Leishmania donovani</i> along with Various Adjuvants Against Experimental Visceral leishmaniasis. ( 29963081 )
2018
28
Risk profile for Leishmania infection in dogs coming from an area of visceral leishmaniasis reemergence. ( 29406075 )
2018
29
Policy Recommendations From Transmission Modeling for the Elimination of Visceral Leishmaniasis in the Indian Subcontinent. ( 29860292 )
2018
30
Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis. ( 29385910 )
2018
31
Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case. ( 29972577 )
2018
32
Serological diagnosis and prognostic of tegumentary and visceral leishmaniasis using a conserved Leishmania hypothetical protein. ( 29408435 )
2018
33
Efficacy of Meglumine Antimoniate under Low Polymerization State Orally Administrated in Murine Model of Visceral Leishmaniasis. ( 29866873 )
2018
34
Hemophagocytic Lymphohistiocytosis: A Confusing Problem of the Diagnosis of Visceral Leishmaniasis. ( 29398821 )
2018
35
Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis. ( 29864949 )
2018
36
Parasitic load and histological aspects in different regions of the spleen of dogs with visceral leishmaniasis. ( 29406277 )
2018
37
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
38
Molecular Diagnosis of Visceral Leishmaniasis. ( 29922885 )
2018
39
Vaccination with a CD4<sup>+</sup> and CD8<sup>+</sup> T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis. ( 29908151 )
2018
40
Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis. ( 29911074 )
2018
41
Serological tests fail to discriminate dogs with visceral leishmaniasis that transmit Leishmania infantum to the vector Lutzomyia longipalpis. ( 28954069 )
2017
42
Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. ( 28091623 )
2017
43
Characterization of Leishmania (L.) infantum chagasi in visceral leishmaniasis associated with hiv co-infection in Northeastern Brazil. ( 28902293 )
2017
44
Visceral leishmaniasis in two patients with IL-12p40 and IL-12RI^1 deficiencies. ( 27873456 )
2017
45
Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform. ( 28873394 )
2017
46
Diagnosis of Mediterranean visceral leishmaniasis by detection of Leishmania-related antigen in urine and oral fluid samples. ( 28017861 )
2017
47
Visceral Leishmaniasis-Malaria Coinfection and Their Associated Factors in Patients Attending Metema Hospital, Northwest Ethiopia: Suggestion for Integrated Vector Management. ( 28932617 )
2017
48
Exome Sequencing Identifies Two Variants of the Alkylglycerol Monooxygenase Gene as a Cause of Relapses in Visceral Leishmaniasis in Children, in Sudan. ( 28586473 )
2017
49
HIF-1I+ is a key regulator in potentiating suppressor activity and limiting the microbicidal capacity of MDSC-like cells during visceral leishmaniasis. ( 28892492 )
2017
50
Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis. ( 28082236 )
2017

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CXCL8 IFNG IL10 IL2 IL4 NOS2
2
Show member pathways
13.44 CXCL8 IL10 IL2 IL4 TLR2 TLR4
3
Show member pathways
13.37 CXCL8 IFNG IL10 IL2 IL4 NOS2
4
Show member pathways
13.04 CXCL8 IFNG IL10 IL2 NOS2 TLR2
5
Show member pathways
12.94 CXCL8 FOXP3 IFNG IL10 IL2 IL4
6
Show member pathways
12.87 IFNG IL2 IL4 TLR2 TLR4 TLR9
7
Show member pathways
12.85 CXCL8 IFNG IL2 IL4 TLR2 TLR4
8 12.84 CXCL8 IFNG IL2 IL4 NOS2
9
Show member pathways
12.73 IL2 TLR2 TLR4 TLR9 TNF
10
Show member pathways
12.71 CXCL8 IFNG IL10 IL2 IL4 TNF
11
Show member pathways
12.62 IFNG IL10 IL2 NOS2 TNF
12 12.59 FOXP3 IFNG IL10 IL2 IL4 TLR2
13
Show member pathways
12.53 TLR2 TLR4 TLR9 TNF
14
Show member pathways
12.48 IFNG IL10 IL2 IL4 TNF
15
Show member pathways
12.4 ALB IFNG IL2 IL4 TNF
16
Show member pathways
12.4 CXCL8 IFNG IL4 TLR2 TNF
17
Show member pathways
12.35 FOXP3 IFNG IL10 IL2 IL4 TLR2
18
Show member pathways
12.34 CXCL8 IFNG NOS2 TLR4 TNF
19
Show member pathways
12.33 CXCL8 TLR2 TLR4 TLR9 TNF
20
Show member pathways
12.31 IFNG IL10 IL2 TLR2 TLR4 TLR9
21
Show member pathways
12.27 IFNG IL10 IL4 NOS2 TLR2 TLR4
22 12.26 IFNG NOS2 TLR2 TLR4 TLR9 TNF
23
Show member pathways
12.25 CXCL8 NOS2 TLR2 TNF
24
Show member pathways
12.24 IL10 IL2 TLR9 TNF
25 12.23 IFNG IL10 NOS2 TLR2 TLR4 TLR9
26
Show member pathways
12.12 CXCL8 IFNG IL10 IL2 IL4
27 12.09 IFNG IL10 IL2 IL4 TNF
28
Show member pathways
12.08 IL2 TLR2 TLR4 TLR9
29 12.07 CXCL8 IL10 IL4 NOS2 TNF
30
Show member pathways
12.03 IFNG IL2 IL4 NOS2
31 11.96 CXCL8 IFNG TLR2 TLR4 TNF
32 11.9 CXCL8 IFNG NOS2 TLR4
33 11.89 IFNG IL10 IL2 IL4 TNF
34 11.88 CXCL8 TLR4 TNF
35 11.88 CXCL8 IFNG IL2 IL4 NOS2 TLR4
36 11.87 CXCL8 IL2 TLR4
37
Show member pathways
11.87 CXCL8 FOXP3 TLR4
38 11.87 CXCL8 IFNG IL2 IL4
39 11.86 CXCL8 IL10 NOS2 TLR4 TNF
40 11.84 IFNG IL10 IL2 TLR9 TNF
41 11.83 TLR2 TLR4 TLR9
42
Show member pathways
11.78 CXCL8 IFNG IL4 NOS2 TLR2 TLR4
43
Show member pathways
11.74 CXCL8 IFNG IL2 NOS2 TNF
44
Show member pathways
11.73 CXCL8 FOXP3 IFNG IL2 IL4 TNF
45
Show member pathways
11.72 FOXP3 IL2 IL4
46 11.69 CXCL8 IL4 TNF
47
Show member pathways
11.68 IFNG IL2 TNF
48 11.68 CXCL8 TLR2 TLR4 TNF
49 11.68 CXCL8 IFNG IL10 NOS2 TLR2 TLR4
50 11.63 CXCL8 IFNG NOS2

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 ALB CXCL8 IFNG IL10 IL2 IL4

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.97 TLR2 TLR4 TLR9 TNF
2 cellular response to lipopolysaccharide GO:0071222 9.96 CXCL8 IL10 NOS2 TLR4 TNF
3 defense response to bacterium GO:0042742 9.95 IL10 NOS2 SLC11A1 TLR4 TLR9 TNF
4 defense response to Gram-negative bacterium GO:0050829 9.92 NOS2 SLC11A1 TLR4 TLR9
5 positive regulation of inflammatory response GO:0050729 9.92 IL2 TLR2 TLR4 TLR9
6 response to lipopolysaccharide GO:0032496 9.91 CXCL8 IL10 NOS2 SLC11A1 TLR2 TLR4
7 positive regulation of JNK cascade GO:0046330 9.9 TLR4 TLR9 TNF
8 regulation of insulin secretion GO:0050796 9.89 IFNG NOS2 TNF
9 positive regulation of tumor necrosis factor production GO:0032760 9.87 TLR2 TLR4 TLR9
10 toll-like receptor signaling pathway GO:0002224 9.87 TLR2 TLR4 TLR9
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 IFNG TLR4 TNF
12 positive regulation of interleukin-6 production GO:0032755 9.87 TLR2 TLR4 TLR9 TNF
13 inflammatory response GO:0006954 9.86 CXCL8 IL10 NOS2 SLC11A1 TLR2 TLR4
14 negative regulation of tumor necrosis factor production GO:0032720 9.85 FOXP3 IL10 TLR4
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 TLR2 TLR4 TLR9 TNF
16 response to bacterium GO:0009617 9.84 NOS2 SLC11A1 TLR4
17 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.83 TLR2 TLR4 TLR9
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TLR2 TLR4 TNF
19 positive regulation of interferon-gamma production GO:0032729 9.83 IL2 SLC11A1 TLR4 TNF
20 negative regulation of interferon-gamma production GO:0032689 9.82 FOXP3 IL10 TLR4
21 positive regulation of interferon-beta production GO:0032728 9.82 TLR2 TLR4 TLR9
22 positive regulation of B cell proliferation GO:0030890 9.81 IL2 IL4 TLR4 TLR9
23 positive regulation of interleukin-10 production GO:0032733 9.8 TLR2 TLR4 TLR9
24 regulation of regulatory T cell differentiation GO:0045589 9.79 FOXP3 IFNG IL2
25 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.78 TLR2 TLR4 TLR9
26 I-kappaB phosphorylation GO:0007252 9.77 TLR2 TLR4 TLR9
27 regulation of cytokine secretion GO:0050707 9.76 TLR2 TLR4 TLR9
28 negative regulation of interleukin-17 production GO:0032700 9.75 FOXP3 IFNG TLR4
29 pentose-phosphate shunt GO:0006098 9.73 PGD TPI1
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 IL10 TNF
31 cellular response to lipoteichoic acid GO:0071223 9.73 TLR2 TLR4
32 macrophage activation GO:0042116 9.73 SLC11A1 TLR4
33 positive regulation of regulatory T cell differentiation GO:0045591 9.72 FOXP3 IL2
34 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 IL2 IL4
35 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
36 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
37 positive regulation of interferon-beta biosynthetic process GO:0045359 9.71 TLR4 TLR9
38 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 IL10 TNF
39 negative regulation of lymphocyte proliferation GO:0050672 9.71 FOXP3 IL2
40 positive regulation of interleukin-8 production GO:0032757 9.71 TLR2 TLR4 TLR9 TNF
41 type 2 immune response GO:0042092 9.7 IL10 IL4
42 negative regulation of interleukin-8 production GO:0032717 9.7 IL10 TLR9
43 negative regulation of T-helper 17 cell differentiation GO:2000320 9.7 FOXP3 IL2
44 positive regulation of toll-like receptor signaling pathway GO:0034123 9.69 TLR2 TLR9
45 tumor necrosis factor production GO:0032640 9.68 TLR2 TLR9
46 regulation of isotype switching GO:0045191 9.68 IL10 IL4
47 positive regulation of killing of cells of other organism GO:0051712 9.68 IFNG NOS2
48 positive regulation of interleukin-18 production GO:0032741 9.68 TLR2 TLR9
49 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IL4 TLR4
50 positive regulation of interleukin-12 production GO:0032735 9.67 IFNG TLR2 TLR4 TLR9

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CXCL8 IFNG IL10 IL2 IL4 TNF
2 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....